Sarepta Therapeutics | SRPT - Cost Of Sales



Sarepta Therapeutics reported $153.22M in Cost of Sales for its fiscal quarter ending in June of 2025.


Cost Of Sales Change Date
Acadia Pharmaceuticals USD 20.73M 342K Jun/2025
Agios Pharmaceuticals USD 1.7M 617K Jun/2025
Alnylam Pharmaceuticals USD 142.95M 71.91M Jun/2025
Amgen USD 3.01B 406M Jun/2025
Biogen USD 605M 24.3M Jun/2025
BioMarin Pharmaceutical USD 154.94M 3.38M Jun/2025
Daiichi Sankyo JPY 92.35B 1.99B Jun/2025
Eli Lilly USD 2.45B 223.6M Jun/2025
Gilead Sciences USD 1.5B 39M Jun/2025
Incyte USD 78.77M 10.96M Jun/2025
Insmed USD 29.34M 8.06M Jun/2025
Ionis Pharmaceuticals USD 4.15M 3.15M Jun/2025
Moderna USD 119M 29M Jun/2025
Neurocrine Biosciences USD 11.3M 2.1M Jun/2025
Pfizer USD 4.99B 2.4B Jun/2025
PTC Therapeutics USD 15.48M 2.62M Jun/2025
Regeneron Pharmaceuticals USD 530.2M 264.7M Jun/2025
Roche Holding CHF 4.13B 393.5M Dec/2024
Sanofi EUR 2.99B 103M Jun/2025
Sarepta Therapeutics USD 153.22M 15.66M Jun/2025
Ultragenyx Pharmaceutical USD 23M 5.66M Jun/2025
Vertex Pharmaceuticals USD 407.5M 44.5M Jun/2025